Morgan Stanley
PBM icon

Morgan Stanley’s Psyence Biomedical PBM Stock Holding History

Morgan Stanley’s Portfolio PBM Stock Details PBM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed -$41 – 8293
2025
Q1 		$41 Buy
+1
New +$64 ﹤0.01% 7790
2024
Q4 		– Sell
-13
Closed -$4.84K – 8115
2024
Q3 		$4.84K Buy
13
+8
+160% +$10.8K ﹤0.01% 6925
2024
Q2 		$6K Buy
+5
New +$15K ﹤0.01% 6808

Other funds holding PBM

PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SFFS
Stonehage Fleming Financial Services St. Helier, Jersey $2.75B AUM 13.81% 1-Year Est. Return

Morgan Stanley's PBM Position: Q2 2025 in Review

Morgan Stanley sold out of Psyence Biomedical (PBM) in Q2 2025, closing a stake of 1 share — an estimated $41 sold.

Morgan Stanley first reported a position in PBM in Q2 2024 and held it in 3 quarters. The position peaked at $6K in Q2 2024. 6 funds tracked by Wall St. Rank hold PBM as of Q2 2025.

  • Morgan Stanley reported no remaining Psyence Biomedical position as of Q2 2025 after selling out during the quarter.
  • Morgan Stanley sold 1 Psyence Biomedical share in Q2 2025, an estimated $41.
  • Morgan Stanley first reported a position in Psyence Biomedical in Q2 2024 and held it in 3 quarters.
  • Morgan Stanley's Psyence Biomedical position peaked at $6K in Q2 2024.
  • 6 funds tracked by Wall St. Rank held Psyence Biomedical as of Q2 2025.

Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.